Figure 1. IFNL genotype and hepatic inflammation and fibrosis.

(a) rs12979860 genotype and hepatic inflammation degree in the cohort of patients with chronic hepatitis C (n=3,129). Pearson’s χ²-test and Fisher’s exact test were used to compare hepatic inflammation rates. (b) rs12979860 genotype and liver fibrosis stage in the cohort of patients with chronic hepatitis C (n=3,129). Pearson’s χ²-test and Fisher’s exact test were used to compare hepatic fibrosis rates. (c) Multivariate cox regressions analysis of rs12979860 genotype on the cumulative probability of progression to moderate/severe (≥F2) fibrosis after adjusting for covariates (age, gender, BMI, duration of the infection, HCV genotype, inflammation progression and basal ALT, AST, GGT, platelets, bilirubin and alkaline phosphatases) in 1,312 patients with an estimated duration of HCV infection. Bars indicate 95% CIs. (d) Stage-specific rates and 95% CIs of fibrosis progression according to rs12979860 genotype in 1,312 patients with an estimated duration of HCV infection. FPRs were obtained using the Markov maximum likelihood estimation. P-values were obtained using a likelihood ratio test comparing models with and without rs12979860 genotype. FPRs were significantly increased for the rs12979860 CC genotype compared with rs12979860 non-CC (P=0.0001). The influence of rs12979860 CC genotype was more important for early compared with late fibrosis stage transitions. Bars indicate 95% CIs.